Showing 3281-3290 of 5246 results for "".
- Researchers Examine UV Nail Salon Lamps and Risk of Skin Cancerhttps://practicaldermatology.com/news/20140501-researchers_examine_uv_nail_salon_lamps_and_risk_of_skin_cancer/2459249/A recent research letter in JAMA Dermatology stated that although using higher-wattage ultra violet (UV) lamps at nail salons to dry and c
- 2014 AAD Election Resultshttps://practicaldermatology.com/news/20140424-2014_aad_election_results/2459257/
- Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™, its Low-energy Radiation Therapy Systems for Treating Skin Cancerhttps://practicaldermatology.com/news/20140331-frost__sullivan_commends_sensus_for_the_development_of_srt-100_and_srt-100_vision_its_low-energy_radiation_therapy_systems_for_treating_skin_cancer/2459289/Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognizes Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation therapy (SRT) in its two lo
- Anti-Interleukin-23 Monoclonal Antibody Guselkumab: Significant Efficacy In Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/20140324-anti-interleukin-23_monoclonal_antibody_guselkumab_significant_efficacy_in_moderate_to_severe_plaque_psoriasis/2459298/New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal a
- Phase I Trial of Nivolumab Shows Long-Term Efficacy Against Melanomahttps://practicaldermatology.com/news/20140313-phase_i_trial_of_nivolumab_shows_long-term_efficacy_against_melanoma/2459318/A recent study by researchers at Dana-Farber Cancer Institute, Johns Hopkins University, Yale University, and allied institutions, published online in the Journal of Clinical Oncology, provides the longest-term look so far at how melanom
- Novartis Announces EU Approval of Xolair for Chronic Spontaneous Urticaria Patients Unresponsive to Antihistamineshttps://practicaldermatology.com/news/20140307-novartis_announces_eu_approval_of_xolair_for_chronic_spontaneous_urticaria_patients_unresponsive_to_antihistamines/2459322/
- Michelson Diagnostics Launches Enhanced Software for VivoSight OCT Scannerhttps://practicaldermatology.com/news/20140219-michelson_diagnostics_launches_enhanced_software_for_vivosight_oct_scanner/2459339/Michelson Diagnostics recently launched its upgraded VivoSight Optical Coherence Tomography (OCT) scanner with a new software technology that provides additional f
- Cosmetic Surgery Forum Offers Early-Bird Registrationhttps://practicaldermatology.com/news/20140204-cosmetic_surgery_forum_offers_early-bird_registration/2459349/
- Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn to Treat Mild to Moderate Acnehttps://practicaldermatology.com/news/20140204-oculus_innovative_sciences_receives_european_ce_mark_for_use_of_microcyn_to_treat_mild_to_moderate_acne/2459350/
- Study Finds Prevalence of Indoor Tanning Common in US, Europe, and Australiahttps://practicaldermatology.com/news/20140130-study_finds_prevalence_of_indoor_tanning_common_in_us_europe_and_australia/2459355/